Biotech Values

[gfp927z]

Biomaven, Looks like PYMX may be starting to recover. I think there was (and still is) a lot of confusion over the antibiotic Phase 2 results last month.

The April press release didn't include the data when analyzed by the same method used in the December interim analysis (April used the new FDA guidelines, while in December they didn't).

They did show analysis by both methods in the April conf call presentation slides, but unfortunately not in the press release, so it was confusing. The April efficacy data was actually better than the 92% data that sent the stock soaring in December -



April data -


Day 3 - (slide 13)
********************

Low Dose - 97.5%

Mid Dose - 91.4%

High Dose - 92.3%

Daptomycin - 91.5%



Day 7 - (slide 13)
********************

Low Dose - 92.5%

Mid Dose - 94.3%

High Dose - 97.4%

Daptomycin - 95.7%




http://investorshub.advfn.com/boards/read_msg.aspx?message_id=75367599